References
- Diabetes facts and figures. Available at http://www.idf.org (Last accessed April 2007)
- 2002 report on the investigation of actual conditions of diabetes. Japan: Ministry of Health, Labour and Welfare, 2004
- UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
- Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675-91
- Pfűtzner A, Schneider C, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 2006;4:445-59
- Dormandy JA, Charbonnel B, Eckland EJA, Erdmann E, Massi-Benedetti M, Moules IK, on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366:1279-89
- Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 2008;299:1561-73
- Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005;7:654-65
- Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007;37:79-86
- Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus;a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409
- Powers AC. Diabetes mellitus. In: Kasper DL,Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL (Eds) Harrison's Principles of Internal Medicine, 16th Edn. McGraw-Hill, 2005, pp. 2152-79
- UK Prospective Diabetes Study Group: UK prospective diabetes study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002;25 (Suppl. 1):S1-S147
- Turner RC, Cull CA, Frighi V, Holmann RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirements for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
- Japan Diabetes Society. Diabetes Mellitus Treatment Guideline Based on Scientific Ground, revised edition 2. Nankodo, 2007, pp. 257-72
- Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004;21:568-76
- Roden M, Laakso M, Johns D, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med 2005;22:1101-6
- Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin 2006;22 (Suppl. 2):S27-S37
- Seufert J. A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. Curr Med Res Opin 2006;22 (Suppl. 2):S39-S48
- Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192-200
- Vergès B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr Med Res Opin 2005;21 (Suppl. 1):S29-S40
- Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007;9:282-9
- Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-80